Design Therapeutics (DSGN) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical platform focused on GeneTAC® molecules, a novel class of small-molecule gene targeted chimera therapeutics for diseases caused by inherited nucleotide repeat expansion mutations, such as Friedreich ataxia, fragile X syndrome, myotonic dystrophy type-1, Fuchs endothelial corneal dystrophy, and Huntington's disease.

• GeneTAC® molecules are designed to modulate gene expression and restore cellular health, with broad applicability across degenerative, monogenic nucleotide repeat expansion diseases.

• Incorporated in Delaware in 2017, with principal offices in Carlsbad, California.

Financial performance and metrics

• Net tangible book value as of March 31, 2025, was approximately $227.9 million, or $4.01 per share.

• After a hypothetical $100 million offering at $4.36 per share, as adjusted net tangible book value would be $324.6 million, or $4.07 per share, resulting in immediate dilution of $0.29 per share to new investors.

• 56,768,678 shares of common stock outstanding as of March 31, 2025, with up to 79,704,457 shares possible post-offering, excluding options and reserved shares.

Use of proceeds and capital allocation

• Net proceeds intended for general corporate purposes, including research and development, clinical trial expenses, capital expenditures, and general and administrative expenses.

• May use a portion for in-licensing, investing in, or acquiring complementary businesses, assets, or technologies, though no current plans or agreements exist.

• Pending use, proceeds will be invested in short and intermediate-term, interest-bearing obligations or investment-grade instruments.